indacaterol/glycopyrrolate

DRUG3 trials

Sponsors

Novartis, Novartis Pharmaceuticals, University of Michigan

Conditions

COPD (Chronic Obstructive Pulmonary Disease)Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00558285

NovartisChronic Obstructive Pulmonary Disease (COPD)

Start: 2007-11-30End: 2008-07-31Updated: 2012-11-30

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00570778

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2007-12-31End: 2008-09-30Updated: 2018-07-26

Phase 3

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

CompletedNCT02867761

University of MichiganCOPD (Chronic Obstructive Pulmonary Disease)

Start: 2017-08-29End: 2021-07-07Updated: 2023-04-13

Related Papers

Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function

New England Journal of Medicine2022-09-0490 citations

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial

Respiratory Research2020-03-1223 citations

Pectoralis muscle area and mortality in smokers without airflow obstruction.

2018-04-1050 citations

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.

2010-10-2677 citations